{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:36:10Z","timestamp":1761129370214},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"44","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1097\/md.0000000000005280","type":"journal-article","created":{"date-parts":[[2016,11,3]],"date-time":"2016-11-03T10:58:36Z","timestamp":1478170716000},"page":"e5280","source":"Crossref","is-referenced-by-count":4,"title":["Anti-HMGCR antibodies in systemic sclerosis"],"prefix":"10.1097","volume":"95","author":[{"given":"Marie","family":"Hudson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yael","family":"Luck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathew","family":"Stephenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"May Y.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mianbo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murray","family":"Baron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marvin J.","family":"Fritzler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-62-20210309","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"R2-62-20210309","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients\u2014the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"key":"R3-62-20210309","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/pds.1603","article-title":"The safety of rosuvastatin in comparison with other statins in over 100,000 statin users in UK primary care","volume":"17","author":"Garcia-Rodriguez","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R4-62-20210309","doi-asserted-by":"crossref","first-page":"e002040","DOI":"10.1136\/bmjopen-2012-002040","article-title":"Assessment of statin-associated muscle toxicity in Japan: a cohort study conducted using claims database and laboratory information","volume":"3","author":"Chang","year":"2013","journal-title":"BMJ Open"},{"key":"R5-62-20210309","doi-asserted-by":"crossref","first-page":"52C","DOI":"10.1016\/j.amjcard.2005.12.010","article-title":"Statin safety: a systematic review","volume":"97","author":"Law","year":"2006","journal-title":"Am J Cardiol"},{"key":"R6-62-20210309","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1056\/NEJMra1515161","article-title":"Statin-associated autoimmune myopathy","volume":"374","author":"Mammen","year":"2016","journal-title":"N Engl J Med"},{"key":"R7-62-20210309","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1097\/01.bor.0000434673.85515.89","article-title":"The spectrum of statin myopathy","volume":"25","author":"Mohassel","year":"2013","journal-title":"Curr Opin Rheumatol"},{"key":"R8-62-20210309","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1212\/NXI.0000000000000124","article-title":"Myopathy with anti-HMGCR antibodies: perimysium and myofiber pathology","volume":"2","author":"Alshehri","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R9-62-20210309","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/MD.0000000000000028","article-title":"Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin","volume":"93","author":"Allenbach","year":"2014","journal-title":"Medicine (Baltimore"},{"key":"R10-62-20210309","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/art.30156","article-title":"Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy","volume":"63","author":"Mammen","year":"2011","journal-title":"Arthritis Rheum"},{"key":"R11-62-20210309","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/art.1780110405","article-title":"Skeletal muscle involvement in progressive systemic sclerosis (scleroderma)","volume":"11","author":"Medsger","year":"1968","journal-title":"Arthritis Rheum"},{"key":"R12-62-20210309","doi-asserted-by":"crossref","first-page":"R50","DOI":"10.1186\/ar3763","article-title":"Clinical significance of antibodies to Ro52\/TRIM21 in systemic sclerosis","volume":"14","author":"Hudson","year":"2012","journal-title":"Arthritis Res Therapy"},{"key":"R13-62-20210309","doi-asserted-by":"crossref","first-page":"R111","DOI":"10.1186\/ar4562","article-title":"Scleroderma-polymyositis overlap syndrome versus idiopathic polymyositis and systemic sclerosis: a descriptive study on clinical features and myopathology","volume":"16","author":"Bhansing","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"R15-62-20210309","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/acr.22451","article-title":"2013 American College of Rheumatology\/European League Against Rheumatism Classification Criteria for Systemic Sclerosis Outperform the 1980 Criteria: data from the Canadian Scleroderma Research Group","volume":"67","author":"Alhajeri","year":"2015","journal-title":"Arthritis Care Res (Hoboken"},{"key":"R16-62-20210309","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S1521-6616(03)00169-4","article-title":"Identification of the B-cell epitopes of the early endosome antigen 1 (EEA1)","volume":"109","author":"Selak","year":"2003","journal-title":"Clin Immunol"},{"key":"R17-62-20210309","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00109-003-0495-y","article-title":"Clinical and serological associations of autoantibodies to GW bodies and a novel cytoplasmic autoantigen GW182","volume":"81","author":"Eystathioy","year":"2003","journal-title":"J Mol Med (Berl"},{"key":"R18-62-20210309","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/jamaneurol.2015.1207","article-title":"Clinical features and treatment outcomes of necrotizing autoimmune myopathy","volume":"72","author":"Kassardjian","year":"2015","journal-title":"JAMA Neurol"},{"key":"R19-62-20210309","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s11926-015-0548-6","article-title":"Immune-mediated necrotizing myopathy: update on diagnosis and management","volume":"17","author":"Basharat","year":"2015","journal-title":"Curr Rheumatol Rep"},{"key":"R20-62-20210309","first-page":"2159","article-title":"A disease severity scale for systemic sclerosis: development and testing","volume":"26","author":"Medsger","year":"1999","journal-title":"J Rheumatol"},{"key":"R21-62-20210309","first-page":"S42","article-title":"Assessment of disease severity and prognosis","volume":"21","author":"Medsger","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"R23-62-20210309","first-page":"458","article-title":"Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization","volume":"35","author":"Hsu","year":"2008","journal-title":"J Rheumatol"},{"key":"R24-62-20210309","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/acr.21583","article-title":"Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis","volume":"64","author":"Steele","year":"2012","journal-title":"Arthritis Care Res (Hoboken"},{"key":"R25-62-20210309","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1056\/NEJMc1506163","article-title":"Intravenous immune globulin for statin-triggered autoimmune myopathy","volume":"373","author":"Mammen","year":"2015","journal-title":"N Engl J Med"},{"key":"R26-62-20210309","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.autrev.2016.07.023","article-title":"Anti-HMGCR antibodies as a biomarker for immune mediated necrotizing myopathies: a history of statins and experience from a large international multi-center study","volume":"15","author":"Musset","year":"2016","journal-title":"Autoimmun Rev"},{"key":"R27-62-20210309","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/mus.23854","article-title":"Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies","volume":"48","author":"Mohassel","year":"2013","journal-title":"Muscle Nerve"},{"key":"R28-62-20210309","doi-asserted-by":"crossref","first-page":"405956","DOI":"10.1155\/2014\/405956","article-title":"Analysis of autoantibodies to 3-hydroxy-3-methylglutaryl-coenzyme A reductase using different technologies","volume":"2014","author":"Musset","year":"2014","journal-title":"J Immunol Res"},{"key":"R29-62-20210309","doi-asserted-by":"crossref","first-page":"R39","DOI":"10.1186\/ar4468","article-title":"Exploring necrotizing autoimmune myopathies with a novel immunoassay for anti-3-hydroxy-3-methyl-glutaryl-CoA reductase autoantibodies","volume":"16","author":"Drouot","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"R30-62-20210309","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/acr.20662","article-title":"Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects","volume":"64","author":"Mammen","year":"2012","journal-title":"Arthritis Care Res (Hoboken"},{"key":"R31-62-20210309","doi-asserted-by":"crossref","first-page":"581","DOI":"10.7326\/0003-4819-137-7-200210010-00009","article-title":"Statin-associated myopathy with normal creatine kinase levels","volume":"137","author":"Phillips","year":"2002","journal-title":"Ann Intern Med"},{"key":"R32-62-20210309","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.autrev.2012.05.011","article-title":"Autoantibodies in systemic sclerosis","volume":"12","author":"Mehra","year":"2013","journal-title":"Autoimmun Rev"},{"key":"R33-62-20210309","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/pgmj.2009.089656","article-title":"Diagnostic utility of anti-Ro52 detection in systemic autoimmunity","volume":"86","author":"Dugar","year":"2010","journal-title":"Postgrad Med J"},{"key":"R34-62-20210309","first-page":"S131","article-title":"Monospecific anti-Ro52\/TRIM21 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects: evidence of an association with interstitial lung disease and worse survival","volume":"33","author":"Wodkowski","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"R35-62-20210309","doi-asserted-by":"crossref","first-page":"484","DOI":"10.2183\/pjab.86.484","article-title":"A historical perspective on the discovery of statins","volume":"86","author":"Endo","year":"2010","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"R36-62-20210309","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nri1839","article-title":"Statin therapy and autoimmune disease: from protein prenylation to immunomodulation","volume":"6","author":"Greenwood","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"R37-62-20210309","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2014.06.005","article-title":"Statin: new life for an old drug","volume":"88","author":"Bifulco","year":"2014","journal-title":"Pharmacol Res"},{"key":"R38-62-20210309","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2165\/11319380-000000000-00000","article-title":"Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment","volume":"33","author":"Chatzizisis","year":"2010","journal-title":"Drug Saf"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000005280","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:36:45Z","timestamp":1620959805000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201611010-00062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":36,"journal-issue":{"issue":"44","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000005280","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]}}}